Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment
Article Abstract:
Genes that are differentially expressed in acute lymphoblastic leukemia (ALL) cells with resistance to four antileukemic drugs are identified and that the pattern of expression of these genes is related to the outcome of treatment is shown. Leukemia cells from 173 children are tested for sensitivity in vitro to prednisolone, vincristine, asparaginase and daunorubicin. Differential expression of a relatively small number of genes is associated with drug resistance and treatment outcome in childhood ALL.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
TGF-beta signaling, tumor suppression and acute lymphoblastic leukemia
Article Abstract:
Among the barriers against abnormal cell is a diverse family of proteins called tumor suppressors, one of which is transforming growth factor beta (TGF-beta). The data suggest the TGF-beta participates in blocking the development of T-lineage acute lymphoblastic leukemia (T-cell All) by suppressing T-cell proliferation.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Mechanisms of disease: acute lymphoblastic leukemia
Article Abstract:
Diagnosis, prognosis and treatment are influenced by the emphasis on recent advances in the knowledge of molecular mechanisms involved in acute lymphoblastic leukemia. Molecular genetic alterations in leukemic cells are examined.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
- Abstracts: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen into 1 and 2 clinical trials
- Abstracts: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. part 2 Novel therapies based on mechanisms of HIV-1 cell entry
- Abstracts: Quantifying the federal minimal risk standard: Implications for pediatric research without a prospect of direct benefit
- Abstracts: Disruption of C/EBP alpha function in acute myeloid leukemia. Genomic aberrations and survival in chronic lymphocytic leukemia